World Diabetes Day is 14th November every year (marking Sir Frederick Banting’s birthday – the scientist who is most famously credited for discovering insulin).
On this day in 2023, Diabetes Australia launched a campaign “Diabetes Research Changes Lives”. Type1Screen’s Dr John Wentworth features in their promotional video talking about the home testing kit for type 1 diabetes screening.
Children identified with type 1 diabetes through a public health screening program tend to have a less severe form of the disease when symptoms emerge.
The Fr1da study group, based in Germany, aimed to see if diagnosing type 1 diabetes in children before they showed symptoms, and providing education and monitoring, could make the condition less severe when symptoms eventuated. Researchers compared two groups: one previously diagnosed early with screening (the Fr1da group), with one diagnosed without screening (often in DKA or ketoacidosis meaning life threateningly high blood sugar levels due to a lack of insulin production).
The screened group had better outcomes at the onset of clinical type 1 diabetes. This exhibited as lower blood sugar levels, lower doses of insulin, and fewer cases of severe diabetic ketoacidosis (DKA). An important observation was the higher fasting C-peptide concentrations and reduced need for insulin therapy in the Fr1da cases, indicating a higher beta cell reserve.
Their findings suggests that early diagnosis, with proactive education and monitoring, can make a significant difference in how children experience the onset of type 1 diabetes.
Media coverage of Type1Screen’s blood spot testing
The at home test kit for type 1 diabetes through Type1Screen has received significant attention this Diabetes Month! This was boosted substantially with thanks to the McCaughley Family.
Lila McCaughley was diagnosed with type 1 diabetes at the age of 9 in DKA (ketoacidosis – a life threatening state where blood sugar levels are too high because the pancreas can no longer produce insulin). In response, her mother Ange Liston-McCaughley founded the Type1Foundation to raise awareness around the signs and symptoms of type 1 diabetes to prevent as many other children as possible experiencing the same horrible diagnosis.
Ange has said that Type1Screen aligns with the values of the Type1Foundation because we too want to identify children and young people at the earliest stages of type 1 diabetes. Screening has been shown to prevent DKA, improve longer term diabetes management, and offers the opportunity for any available clinical trials to delay or prevent type 1 diabetes.
So when Ange decided to get herself, and the rest of her family screened for type 1 diabetes using the new at home blood spot test with Type1Screen, the type 1 diabetes community took notice! And so too did the media. Thanks to the McCaughley family for their ongoing support and their amazing media skills!
For all the media coverage you can click on these links:
Community Engagement Panel Members sought for ATIC
The Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) brings together researchers, clinicians and advocates to identify and create immunotherapy clinical trial opportunities for people at every age and every stage of type 1 diabetes (T1D).
Supported by JDRF Australia, ATIC is led by St Vincent’s Institute of Medical Research (SVI) in Melbourne and involves multiple major type 1 diabetes centres across Australia and New Zealand.
Core to ATIC’s success is involvement of the broader type 1 diabetes community – people living with the condition, their families and advocates. People with first-hand experience of T1D are sought to join the ATIC Community Engagement Panel.
If you’re passionate about improving the lives of people with type 1 diabetes through immunotherapy research and ultimately treatments to delay and prevent T1D, don’t miss your chance to be a part of this exciting opportunity.
Applications are being accepted until COB Friday 2 December.
More information is available on the ATIC website:
Screening for Type 1 Diabetes decreases ketoacidosis and preserves beta cell function
A recent paper authored by our lead Type1Screen clinicians has demonstrated clearly that screening relatives for Type 1 Diabetes decreases ketoacidosis and preserves beta cell function for those in identified in the earliest stages of T1D.
You can read the full paper here and listen to John Wentworth being interviewed about it here.
Thanks to the amazing McCaughley Family for supporting the bloodspot screening program by getting their whole family tested and sharing the experience online and via the Herald Sun.
So you have a family member diagnosed with type 1 diabetes, and you’ve heard about the new and easy finger prick blood spot test you can do at home. This test will help to assess your, or your child’s, risk for type 1 diabetes.
OK, it sounds easy, but can I really do it myself at home?
Dr John Wentworth will show you how in this short video.
The Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) officially launched at the Australasian Diabetes Congress in Brisbane on the 10th August 2022.
What is ATIC?
The Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) is a clinical trials network of adult and paediatric endocrinologists, immunologists, clinical triallists and members of the type 1 diabetes (T1D) community.
Immunotherapies have been shown to blunt the immune attack on the pancreas that occurs in people with type 1 diabetes. ATIC’s work will discover the safest and most effective immunotherapy treatments.
The ATIC team are working across six domains with the bold vision to fast-track immunotherapy treatment options for people with type 1 diabetes.
Clinical Trials: Implement immunotherapy trials for type 1 diabetes
Community Engagement: Ensure ATIC’s work meets the needs of people living with type 1 diabetes
Pre-clinical & Translation: Help transform scientific discoveries into effective treatments
Data management: Facilitate data driven research
Education and training around the fundamentals of immunotherapy, and the latest research on its use in type 1 diabetes
Advocacy, regulation and government: Drive regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
ATIC facilitates immunotherapy clinical trials across a network of leading clinical trial centres. ATIC can advise on mechanisms for obtaining trial funding, assist with initial ethics approvals, oversee trial conduct, and support participant recruitment efforts to ensure clinical trials are delivered on time and within budget.
We have just rolled out finger prick tests that families can perform at home and mail back to our lab. Our new antibody assay allows us to get a result back to families a little sooner than the standard assay based on a formal blood collection.
diagnosis of type 1 diabetes is really important. It allows us to monitor
children for signs of progression and, if this occurs, to start insulin
injections in good time and prevent serious illness, which currently affects a
third of our children. Not all positive screens progress quickly and in many
cases we have time to offer opportunities to join immunotherapy prevention
We really hope that the blood spot screening test will make it much easier for families to access screening, particularly those living in regional communities.
If you would like to see just how simple it is to get screened, please contact us to receive a kit to use at home. If you want to help us spread the word about this program, please tag us online @Type1Screen.
Ultimately, we want to make screening accessible to every Australian child. Type1Screen will take us closer to this goal by demonstrating to the world that we can perform cheap and accurate screening in a timely manner and at scale.
Type1Screen is supporting the enrolment of young adults with a recent diagnosis of type 1 diabetes (T1D) to a new drug trial. This randomized, placebo-controlled, multi-centre clinical trial will evaluate the treatment of the Imotope™ IMCY-0098 and its effect on the preservation of beta-cell function in people with a recent onset T1D.
The study aims to investigate the effect of two doses of IMCY-0098 upon treatment-specific biomarkers and the effect of study medication on beta-cell function in adults with recently diagnosed type 1 diabetes.
Eligibility to take part
Aged 18 to 44 years
Diagnosed with type 1 diabetes (first insulin treatment) within 9 weeks of study screening visit.